Search

Your search keyword '"Marazzato M"' showing total 60 results

Search Constraints

Start Over You searched for: Author "Marazzato M" Remove constraint Author: "Marazzato M"
60 results on '"Marazzato M"'

Search Results

1. OC.15.5: POLIPROTECT IS AN EFFECTIVE TREATMENT TO MANAGE PPI DEPRESCRIBING. A RANDOMIZED CONTROLLED TRIAL (RCT) POST HOC ANALYSIS

2. T.01.4: PATIENTS WITH NONEROSIVE HEARTBURN AND EPIGATRIC PAIN SYNDROME (EPS) ARE NOT CLINICALLY DISTINGUISHABLE AND BENEFIT OF THE SAME TREATMENT. A RANDOMIZED CONTROLLED TRIAL (RCT) POST HOC ANALYSIS

3. T.01.11 AN RC TRIAL COMPARING THE MUCOSAL PROTECTIVE AGENT (MPA) POLIPROTECT (NEOBIANACID®) (P) AND OMEPRAZOLE (O) IN THE TREATMENT OF HEARTBURN AND EPIGASTRIC PAIN/BURNING IN NON-EROSIVE REFLUX DISEASE (NERD) AND EPIGASTRIC PAIN SYNDROME (EPS)

6. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19

7. Bacterial biofilm associated with a case of capsular contracture

11. Plasmid-mediated fluoroquinolone resistance determinants in Escherichia coli from community uncomplicated urinary tract infection in an area of high prevalence of quinolone resistance

12. Features of uropathogenic Escherichia coli able to invade a prostate cell line

13. Women Skin Microbiota Modifications during Pregnancy.

14. Chronic intestinal pseudo-obstruction: associations with gut microbiota and genes expression of intestinal serotonergic pathway.

15. Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.

16. SLAB51 Multi-Strain Probiotic Formula Increases Oxygenation in Oxygen-Treated Preterm Infants.

17. Atopic dermatitis-derived Staphylococcus aureus strains: what makes them special in the interplay with the host.

18. The effect of probiotic administration on metabolomics and glucose metabolism in CF patients.

19. Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients.

20. Gut Microbiota Structure and Metabolites, Before and After Treatment in Early Rheumatoid Arthritis Patients: A Pilot Study.

21. Extraintestinal Pathogenic Escherichia coli : Beta-Lactam Antibiotic and Heavy Metal Resistance.

22. Genetic Diversity of Antimicrobial Resistance and Key Virulence Features in Two Extensively Drug-Resistant Acinetobacter baumannii Isolates.

23. Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients.

24. Allergic rhinitis, microbiota and passive smoke in children: A pilot study.

25. Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota?

26. Oxygen Sparing Effect of Bacteriotherapy in COVID-19.

27. Resveratrol-Loaded Nanoemulsions: In Vitro Activity on Human T24 Bladder Cancer Cells.

29. Nanoemulsions of Satureja montana Essential Oil: Antimicrobial and Antibiofilm Activity against Avian Escherichia coli Strains.

30. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.

31. Escherichia coli strains of chicken and human origin: Characterization of antibiotic and heavy-metal resistance profiles, phylogenetic grouping, and presence of virulence genetic markers.

32. 16S Metagenomics Reveals Dysbiosis of Nasal Core Microbiota in Children With Chronic Nasal Inflammation: Role of Adenoid Hypertrophy and Allergic Rhinitis.

33. Insight into the Possible Use of the Predator Bdellovibrio bacteriovorus as a Probiotic.

34. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.

35. Efficacy of Pidotimod use in treating allergic rhinitis in a pediatric population.

36. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.

37. Nasal Microbiota in RSV Bronchiolitis.

38. Bovine Lactoferrin Pre-Treatment Induces Intracellular Killing of AIEC LF82 and Reduces Bacteria-Induced DNA Damage in Differentiated Human Enterocytes.

39. Virulence behavior of uropathogenic Escherichia coli strains in the host model Caenorhabditis elegans.

40. Satureja montana L. essential oil and its antimicrobial activity alone or in combination with gentamicin.

41. Bacterial biofilm associated with a case of capsular contracture.

42. Genetic diversity, phylogroup distribution and virulence gene profile of pks positive Escherichia coli colonizing human intestinal polyps.

43. Coriander (Coriandrum sativum) Essential Oil: Effect on Multidrug Resistant Uropathogenic Escherichia coli.

44. Molecular characterisation of extensively drug-resistant Acinetobacter baumannii: First report of a new sequence type in Italy.

45. The Adherent/Invasive Escherichia coli Strain LF82 Invades and Persists in Human Prostate Cell Line RWPE-1, Activating a Strong Inflammatory Response.

46. The Shigella flexneri OmpA amino acid residues 188 EVQ 190 are essential for the interaction with the virulence factor PhoN2.

47. Features of uropathogenic Escherichia coli able to invade a prostate cell line.

48. Influenza A virus infection of intestinal epithelial cells enhances the adhesion ability of Crohn's disease associated Escherichia coli strains.

49. Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features.

50. Lactoferrin differently modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases.

Catalog

Books, media, physical & digital resources